Lexeo Therapeutics (LXEO) Depreciation & Amortization (CF) (2022 - 2026)
Lexeo Therapeutics (LXEO) posted Depreciation & Amortization (CF) of $73000.0 for Q1 2026, little changed sequentially from $73000.0 in Q4 2025, and up 21.67% YoY from $60000.0 in Q1 2025.
Lexeo Therapeutics (LXEO) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Depreciation & Amortization (CF) for 5 years, with the latest figure at $73000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 21.67% year-over-year to $73000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281000.0 (down 4.75% YoY) and the FY2025 annual result came in at $268000.0, down 11.84% from the prior year.
- Depreciation & Amortization (CF) steadied at $73000.0 in Q1 2026 per LXEO's latest filing, from $73000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $83000.0 in Q3 2024 and troughed at $57000.0 in Q1 2023.
- A 5-year average of $69571.4 and a median of $73000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) surged 32.76% in 2023, then dropped 19.48% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $58000.0 in 2022, then surged by 32.76% to $77000.0 in 2023, then slipped by 2.6% to $75000.0 in 2024, then fell by 2.67% to $73000.0 in 2025, then changed by 0.0% to $73000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $73000.0, $73000.0, and $73000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | 74,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74,000.00 |
| Jun 30, 2026 | 74,000.00 |
| Mar 31, 2026 | 73,000.00 |
| Mar 31, 2026 | 73,000.00 |
| Dec 31, 2025 | 73,000.00 |
| Dec 31, 2025 | 73,000.00 |
| Sep 30, 2025 | 73,000.00 |
| Sep 30, 2025 | 73,000.00 |
| Jun 30, 2025 | 62,000.00 |
| Jun 30, 2025 | 62,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Dec 31, 2024 | 75,000.00 |
| Dec 31, 2024 | 75,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Mar 31, 2024 | 69,000.00 |
| Mar 31, 2024 | 69,000.00 |